Enterprise Value
27.51M
Cash
13.33M
Avg Qtr Burn
-5.00M
Short % of Float
0.66%
Insider Ownership
1.93%
Institutional Own.
8.00%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XACIATO (DARE-BV1) Details Bacterial infection | Approved Quarterly sales | |
Sildenafil Cream, 3.6% Details Sexual dysfunction, Sexual desire disorder | Phase 3 Initiation | |
Ovaprene® Details Contraceptive | Phase 3 Initiation | |
DARE-PDM1 Details Primary dysmenorrhea | Phase 1 Data readout | |
DARE-VVA1 (Tamoxifen formulation) Details Vulvovaginal Candidiasis | IND Submission | |
DARE-HRT1 Details Menopause | IND Submission |